4basebio launches enzymatic ssDNA platform for gene editing applications
Tuesday, May 12, 2026
4basebio PLC has launched a high-capacity single-stranded DNA (ssDNA) platform designed to support the development of gene editing and nucleic acid-based therapies.
The new product line uses a proprietary enzymatic manufacturing process to produce high-purity, long-form ssDNA templates with protected ends. The company said the platform is intended to address manufacturing and performance challenges linked to traditional chemical synthesis methods used in CRISPR-based gene editing.
According to 4basebio, demand for longer and higher-purity DNA templates has increased with the growth of gene editing technologies, particularly for complex “knock-in” applications. The platform can produce ssDNA constructs of up to 10,000 nucleotides with protected ends to improve stability, reduce immunogenicity and support clinical-scale manufacturing.
The company said the technology could help advance targeted gene editing, cell engineering and other next-generation genetic therapies.
Technical data related to the platform will be presented at the upcoming American Society of Gene & Cell Therapy Annual Meeting in Boston. Amine Bouchareb, Director of Molecular Biology and Gene Editing at 4basebio, is scheduled to present findings on the enzymatic ssDNA platform and its role in non-viral CRISPR gene editing.
4basebio stated that the platform aims to overcome limitations associated with double-stranded DNA toxicity and the size restrictions of chemically synthesised oligonucleotides.
The company also reported that its long-form ssDNA constructs demonstrated improved homology-directed repair (HDR) gene editing efficiency while maintaining higher cell viability in sensitive primary cell types.
Source: globenewswire.com/
